Funding Boost for Needle-Free Vaccine

by Kathy Jones on  August 4, 2011 at 6:40 PM Research News
RSS Email Print This Page Comment
Font : A-A+

The research for needle-free vaccine received a major boost after a group of investors pledged over $15 million for the research currently undergoing at the Australian Institute for Bioengineering and Nanotechnology.
 Funding Boost for Needle-Free Vaccine
Funding Boost for Needle-Free Vaccine

The investment was made by a group of international biotechnology firms such as Medial Research Commercialisation Fund and US-based HealthCare Ventures along with venture capital firms One Venture and Brandon Capital.

The investment will allow Professor Mark Kendall to continue his research into the technology, known as Nanopatch that promises to deliver vaccine to immune cells in the skins rather than the traditional method of delivering it through a syringe.

Latest trials of nanopatch revealed that the flu vaccination delivered through this method was effective using just 1/150th of the dose compared to a syringe.

Stating that the nanopatch will prevent cross-contamination, Professor Kendall said, "The Nanopatch offers a way to stop needle-stick injuries during vaccination which again is a particularly important problem in Africa; with a third of vaccines affected by other complications brought about through cross contamination needle stick injury."

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive